Please reload

Recent Posts

Sage Group Represents Solvotrin to License Their Novel ActiveIronTM Product Portfolio

August 3, 2018

1/2
Please reload

Featured Posts

Moberg's BUPIZENGE™ - Sage Group Offers An Opportunity for Leadership in Pain Relief for Oral Mucositis and Other Conditions with Severe Oral Pain

September 7, 2018

Stockholm, Sweden, 8 September 2018 – Moberg has appointed The Sage Group to lead the BUPIZENGE™ partnering program.

 

Moberg Pharma is a rapidly growing, publicly-traded, Swedish pharmaceutical company that commercializes proprietary and acquired products in the global market. Initially, the company specialized in innovative topical treatments in niche indications but is now focusing on skin and nails conditions Moberg markets OTC brands in the U.S. and sell through distributors in more than 30 countries. BUPIZENGE™ is among its main out licensing / partnering products.

 

Peter Wolpert, CEO of Moberg, said “BUPIZENGE™ has the potential to become the leader in pain relief for oral mucositis and other conditions with severe oral pain.”

 

Key Points About BUPIZENGE™

  • An innovative patented lozenge - BUPIZENGE™ is a novel lozenge formulation of bupivacaine, a well-established local anaesthetic.

Issued and long-life patents

  • Patent granted in the U.S, Canada and EU. until 2033

 

A well established molecule

  • Bupivacaine, the active ingredient in BUPIZENGE™, is a local anaesthetic of the amide type which has been used in many licensed medicinal products for years, including epidural infusions and solutions for injections.

  • The mode of action and pharmacological properties of local anaesthetics including bupivacaine are well established.

  • Substantial data for BUPIZENGE™ and information on efficacy and general safety of bupivacaine in the literature.

 

Highly statistically significant Phase 2 results

  • Primary endpoint: 31% less pain in BUPIZENGE™ group (Highest VAS score in mouth/pharynx, p=0.0032

  • In Mouth only: 50% less pain in BUPIZENGE™ group (p=0.0002)

  • Longer duration of action with a statistically significant (p= 0.0004) lower pain score before the intake of next dose compared to SoC

  • No serious adverse reactions associated with BUPI; plasma concentrations of bupivacaine below toxic levels

 

Target Product Profile

  • Self administration on an “as-needed” basis: 1 lozenge every 3 hours when required for pain relief

  • Rapid onset of action (within minutes),

  • Provides up to 3 hours of pain relief (clinically significant downward shift on VAS pain scale)

    Stimulates salivation (patients at risk of xerostomia)

  • Easy to use to improve compliance (in self-care setting)

  • Safe (no systemic mode of action, no significant side effects)

  • Can be made available in several different flavors; i.e. liquorice, menthol…

 

For more information about Moberg Pharma and partnering opportunities for its Bupizenge product, please contact:

 

Dr. Bill Mason
The Sage Group
The Old Black Barns
Lord’s Lane, Ousden  CB8 8TX  UK
Tel: +44 (0) 7785 950134
wtm@sagehealthcare.com

 

Or

 

Wayne Pambianchi
The Sage Group Inc.
1802 Route 31 North
 #381 Clinton
New Jersey  08809 USA

 

Share on Facebook
Share on Twitter
Please reload

Follow Us
Please reload

Search By Tags